The Food and Drug Administration (FDA) granted a priority review to atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) for frontline use in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease expresses the PD-L1 protein.
The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
The FDA has granted pembrolizumab (Keytruda) an accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar), according to Merck, the manufacturer of the PD-1 inhibitor.
The fast pace of development in the immunotherapy and targeted therapy space has outstripped the availability of head-to-head comparative data for adjuvant melanoma treatment. Therefore, Hussein Tawbi, MD, PhD, recommended for healthcare professionals to communicate the relative merits and risks of both options to patients and making a shared decision.
Selinexor has been granted a fast track designation by the Food and Drug Administration (FDA) to treat previously treated patients with diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy.
There is an increasing need for board-certified genetic counselors in the United States, says Stephanie A. Cohen, MS, LCGC, and she is looking to nurses to help improve patient access to hereditary cancer risk assessment and genetic testing.
The combination use of adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) has continued to show a significant relapse-free survival benefit among patients with resected stage III BRAF-mutant melanoma.
Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.
Patients with advanced cancers associated with NTRK gene fusions showed an 80% objective response rate (ORR) with larotrectinib, a TRK inhibitor, according to pooled results from 3 small trials.
The FDA has approved elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.
The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
Frontline alectinib (Alecensa), a next-generation tyrosine kinase inhibitor, enabled Asian patients with untreated ALK-positive advanced non–small cell lung cancer (NSCLC) to live significantly longer without disease progression compared with those who were treated with crizotinib (Xalkori) as initial therapy.
The Food and Drug Administration approved pegfilgrastim-cbqv (Udenyca), a biosimilar to pegfilgrastim (Neulasta).
After a computerized assessment, patients choose between traditional or virtual therapy.
The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).
Trifluridine/tipiracil (FTD/TPI; Lonsurf) reduced the risk of death in patients with heavily pretreated gastric or gastroesophageal junction (GEJ) cancer by 31% compared with placebo, according to data from the phase III TAGS trial.
A panel of experts gathered at a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix to exchange their thoughts on the practical and theoretical considerations of incorporating biosimilars into the healthcare ecosystem.
Treatment for multiple myeloma is quickly evolving. To bring physicians, nurses, and other members of the community oncology care team up to date, Abhinav B. Chandra, MD, MSc, FACP, conducted a presentation at the Association of Community Cancer Centers (ACCC) 35th National Oncology Conference in Phoenix, Arizona.
Here are the top 5 Oncology Nursing News stories for October 2018.
At the Association of Community Cancer Centers (ACCC) 35th National Oncology Conference, Jessica Clague DeHart, PhD, MPH, discussed how clinicians can communicate the importance of physical activity and good nutrition practices to patients.
The FDA has approved pembrolizumab (Keytruda) for first-line use in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).
How can oncology teams become more resilient in the face of growing professional challenges?
Though many patients with HPV-positive oropharyngeal cancer have been treated with cetuximab (Erbitux), results from the international De-ESCALaTE HPV trial showed that chemoradiotherapy, the current standard of care, is still the most effective.
The Food and Drug Administration has granted a priority review to the supplemental new drug application for ruxolitinib (Jakafi) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
The Food and Drug Administration (FDA) has granted a priority review to the oral chemotherapy TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Pet dogs help find cures for cancer.
The FDA has added 3 months to the review period for
To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations. Financial advocates may be financial counselors, nurses, navigators, social workers; pharmacy technicians; practice managers, and others.
The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.
The FDA has granted a priority designation to a supplemental new drug application (sNDA) for ibrutinib (Imbruvica) for use in combination with obinutuzumab (Gazyva) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
